Mersana Therapeutics Announces Additional Interim Phase 1 Clinical Data For Emiltatug Ledadotin, B7-H4-Directed Dolasynthen ADC

Author: Benzinga Newsdesk | June 02, 2025 08:16am

• 31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses
  • 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy

CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced additional interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660), the company's B7-H4-directed Dolasynthen ADC. These data are being presented in an oral session today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, Illinois.

The presentation will focus on Emi-Le's Phase 1 dose escalation and backfill cohorts as of a March 8, 2025 data cut-off in patients with triple-negative breast cancer (TNBC); hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; ovarian cancer; endometrial cancer and adenoid cystic carcinoma type 1 (ACC-1).

Posted In: MRSN